Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 6Neuroblastoma 2Meningioma 2Medulloblastoma 2Recurrence 1Lymphoma, Mantle-Cell 1

Interventions

Magnetic Resonance Spectroscopy 12gallium Ga 68 dotatate 6Everolimus 6lutetium Lu 177 dotatate 5Radiosurgery 5Proton Therapy 5Bevacizumab 5pembrolizumab 4Surveys and Questionnaires 4Specimen Handling 4Hydroxyurea 4abemaciclib 3Tranexamic Acid 3Surgical Procedures, Operative 3Sodium Chloride 3Ga(III)-DOTATOC 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vistusertib 2trametinib 2ribociclib 2arginyllysine 2aldesleukin 2Yoga 2Whole Body Imaging 2Sunitinib 2Saline Solution 2Ropivacaine 2Radiotherapy 2Protons 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Meningioma × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03013387 2017-08-25

Dosimetry Guided PRRT With 90Y-DOTATOC

University of Iowa

Phase 2 Withdrawn
CNS

Medulloblastoma, Meningioma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡